Public Health Advisory: Mix-Up of Opiate Products

A public health advisory regarding potential safety risk with opiate products has been issued:

FDA is advising healthcare professionals and patients of a potential problem with opiate products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska manufacturing site. Due to problems that occurred when these products were packaged and labeled at the site, tablets from one product type may have carried over into packaging of another product. This could result in a stray pill of one medicine ending up in the bottle of another product.

The following products are included:

• Opana ER (oxymorphone hydrochloride) Extended-Release Tablets CII
• Opana (oxymorphone hydrochloride) CII
• Oxymorphone hydrochloride Tablets CII
• PERCOCET (oxycodone hydrochloride and acetaminophen USP) Tablets CII
• PERCODAN (oxycodone hydrochloride and aspirin, USP) Tablets CII
• ENDOCET (oxycodone hydrochloride and acetaminophen USP) Tablets CII
• ENDODAN (oxycodone hydrochloride and aspirin, USP) Tablets CII
• MORPHINE SULFATE Extended-Release Tablets CII
• ZYDONE (hydrocodone bitartrate/acetaminophen tablets, USP) CIII

Please be sure to check the contents of your prescriptions carefully. All of the pills in the bottle should look the same. If the pills don't look like what you normally take or if you find any pills that are different in shape, size, color, or markings, take them to your pharmacist right away.

Endo Pharmaceuticals has provided a visual guide of the affected drugs that you can download if you would like to double check the tablets in your prescription: Endo Pharmaceuticals Opioid Guide.